Sangamo Therapeutics Inc (SGMO)

9.45
0.00 (0.00)
NASDAQ : Health Care
Prev Close 9.45
Open 9.45
Day Low/High 9.10 / 9.55
52 Wk Low/High 4.63 / 9.91
Volume 970.62K
Avg Volume 1.66M
Exchange NASDAQ
Shares Outstanding 83.44M
Market Cap 792.67M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Short Interest Drops 16% For SGMO

Short Interest Drops 16% For SGMO

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 1,569,691 share decrease in total short interest for Sangamo Therapeutics Inc , to 8,230,673, a decrease of 16.02% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

We're Swimming in a Sea of Green This A.M.

We're Swimming in a Sea of Green This A.M.

There are few standout stocks, but there is broad strength so far today.

Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers

Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers

Seattle Genetics, FibroGen and Sangamo were among the biotech stock movers in premarket trading on June 26.

Shark Bites: Move Along, No Volatility to See Here

Shark Bites: Move Along, No Volatility to See Here

Only minor movement in the market.

Biotech Movers: Sangamo, Epizyme, Revance

Biotech Movers: Sangamo, Epizyme, Revance

Sangamo Therapeutics, Epizyme and Revance were among the biotech stock movers in premarket trading on June 21.

Sangamo Therapeutics Stock Sees Short Interest Make 16.5% Move

The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 1,311,426 share increase in total short interest for Sangamo Therapeutics Inc , to 9,274,371, an increase of 16.47% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Market Brushes Off Comey for More Interesting News

Market Brushes Off Comey for More Interesting News

Alibaba and Nordstrom are helping the bulls.

Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency

Companies also Announce Phase 1/2 Clinical Trial Evaluating SB-525 in Adults with Severe Hemophilia A is Now Open for Enrollment

Shark Bites: Focus on the 'Little Picture'

Shark Bites: Focus on the 'Little Picture'

Here's what I'm trading today amid the 'flat with a positive tone' action.

Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy

Collaboration combines Pfizer's heritage in Rare Disease, capabilities in gene therapy, and expertise in hemophilia with Sangamo's deep knowledge in genomic therapies

Biotech Movers: Aratana Offering Priced Below Market, Shares Fall

Biotech Movers: Aratana Offering Priced Below Market, Shares Fall

Aratana Therapeutics, Trevena and Sangamo Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Sangamo Therapeutics Announces Special Regulatory Designations From The FDA For Three Clinical Programs

Rare Pediatric Disease Designation for SB-913 In Vivo Genome Editing Treatment for MPS II

Biotech Premarket Movers: Vertex, Sangamo, Depomed

Biotech Premarket Movers: Vertex, Sangamo, Depomed

Vertex Pharmaceuticals, Sangamo Therapeutics and Depomed were among the biotech stock movers in premarket trading on Wednesday.

Sangamo Therapeutics Announces Presentation Of New Data Demonstrating Significant Reduction Of Tau Expression Using Proprietary ZFP Gene Regulation Technology

Engineered Zinc Finger Protein Transcription Factors Lowered Tau Levels by More Than 90% in Human Neurons In Vitro and Reduced Neuritic Dystrophy in Amyloid Mouse Model of Alzheimer's Disease

Commit To Purchase Sangamo Therapeutics At $3, Earn 20.4% Annualized Using Options

Investors eyeing a purchase of Sangamo Therapeutics Inc stock, but tentative about paying the going market price of $4.18/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $3 strike, which has a bid at the time of this writing of 50 cents.